New Vaccines for Chronic Respiratory Patients

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia, e Pediatríaes_ES
dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicinaes_ES
dc.contributor.authorMallah, Narmeen
dc.contributor.authorDacosta Urbieta
dc.contributor.authorDacosta Urbieta, Ana Isabel
dc.contributor.authorRivero Calle, Irene
dc.contributor.authorGonzález Barcala, Francisco Javier
dc.contributor.authorBigoni, Tommaso
dc.contributor.authorPapi, Alberto
dc.contributor.authorMartinón Torres, Federico
dc.date.accessioned2024-09-13T12:33:42Z
dc.date.available2024-09-13T12:33:42Z
dc.date.issued2024
dc.description.abstractChronic respiratory diseases (CRD) are responsible for more than four million deaths worldwide and have become especially prevalent in developed countries. Although the current therapies help manage daily symptoms and improve patients’ quality of life, there is a major need to prevent exacerbations triggered mainly by respiratory infections. Therefore, CRD patients are a prime target for vaccination against infectious agents. In the present manuscript we review the state of the art of available vaccines specifically indicated in patients with CRDs. In addition to pneumococcus, influenza, pertussis, and SARS-CoV-2 vaccines, recently added immunization options like vaccines and monoclonal antibodies against respiratory syncytial virus, are particularly interesting in CRD patients. As new products reach the market, health authorities must be agile in updating immunization recommendations and in the programming of the vaccination of vulnerable populations such as patients with CRDs. Organizational and educational strategies might prove useful to increase vaccine uptake by CRD patients.es_ES
dc.description.peerreviewedSIes_ES
dc.description.sponsorshipThis work was supported by consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CB21/06/00103; F.M-T), DIAVIR (Instituto de Salud Carlos III [ISCIII]/DTS19/00049/Cofinanciado FEDER; Proyecto de Desarrollo Tecnológico en Salud), Resvi-Omics (Instituto de Salud Carlos III [ISCIII]/PI19/01039/Cofinanciado FEDER), BI-BACVIR (PRIS-3; Agencia de Conocimiento en Salud [ACIS]-Servicio Gallego de Salud [SERGAS]-Xunta de Galicia; Spain), Programa Traslacional COVID-19 (ACIS-Servicio Gallego de Salud [SERGAS]-XUNTA de Galicia; Spain) and Axencia Galega de Innovación (GAIN; IN607B 2020/08-XUNTA de Galicia; Spain); and ReSVinext (Instituto de Salud Carlos III [ISCIII]/PI16/01569/Cofinanciado FEDER), Enterogen (Instituto de Salud Carlos III [ISCIII]/PI19/01090/Cofinanciado FEDER), OMI-COVI-VAC (PI22/00406/Cofinanced European Regional Development Fund), Grupos de Referencia Competitiva (IIN607A2021/05) and Axencia Galega de Innovación (GAIN; IN845D 2020/23-Xunta de Galicia; Spain).es_ES
dc.identifier.citationArchivos de Bronconeumología Volume 60, Issue 9 , September 2024, Pages 565-575es_ES
dc.identifier.doi10.1016/j.arbres.2024.05.026
dc.identifier.issn0300-2896
dc.identifier.urihttp://hdl.handle.net/10347/34785
dc.journal.titleArchivos de Bronconeumología
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights© 2024 The Authors. Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY-NC-ND licensees_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectChronic respiratory diseaseses_ES
dc.subjectInfluenzaes_ES
dc.subjectPertussises_ES
dc.subjectPneumococcal disease vaccinees_ES
dc.subjectRespiratory syncytial viruses_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectVaccinees_ES
dc.subjectMonoclonal antibodyes_ES
dc.titleNew Vaccines for Chronic Respiratory Patientses_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublication7532a4d0-9488-4bc6-bf59-f432c9d4562b
relation.isAuthorOfPublication4cbca26f-0f1c-4cf9-88a5-60e52fa8b217
relation.isAuthorOfPublication1edfc6d6-58bb-425b-a52a-d2b495d0bb3d
relation.isAuthorOfPublication.latestForDiscovery4cbca26f-0f1c-4cf9-88a5-60e52fa8b217

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2.0-S030028962400190X-main.pdf
Size:
587.88 KB
Format:
Adobe Portable Document Format
Description:
Artigo principal